Pfizer Closes Only Bay Area Office in South San Francisco, Shifting Staff Remote

Pfizer's three-year Bay Area chapter is closing. The pharmaceutical giant confirmed it will vacate its 164,000-square-foot research and office campus at 181 Oyster Point Blvd. in South San Francisco by April 30, shifting all employees assigned to the site into remote roles and listing the building's specialized lab and office space for sublease.

Spokesperson Jerica Pitts offered a terse explanation: "After careful evaluation, Pfizer has decided to close its South San Francisco office as the office space is currently underutilized." Pitts added that "Pfizer continues to maintain a strong presence in California, including its facilities in San Diego."

Pfizer first established its Bay Area foothold in 2022 through its $5.4 billion acquisition of Global Blood Therapeutics, a South San Francisco-based sickle cell disease biotech whose Oyster Point headquarters became Pfizer's sole Bay Area address. The signs of retrenchment came quickly: by 2024, the company was already seeking a subtenant for roughly 91,000 square feet, more than half of the building, before ultimately deciding on a full exit.

The closure is a direct product of a cost-reduction campaign led by CEO Albert Bourla, targeting $7.7 billion in total savings by 2027, a program rooted in the steep revenue decline that followed Pfizer's pandemic peak, when COVID vaccine and antiviral sales inflated the company's balance sheet before evaporating almost as rapidly. Rather than consolidating Bay Area staff at another regional site, Pfizer has been investing southward: the company recently relocated its oncology research operations into a new 230,000-square-foot campus at Torrey Heights in San Diego.

A WARN Act notice filed earlier in 2024 documented 52 layoffs at the South San Francisco facility. The total number of employees transitioning to remote work has not been publicly disclosed.

The departure lands on a market already in structural retreat. Life sciences vacancy in the South San Francisco submarket reached roughly 35 percent in the fourth quarter of 2025, according to CBRE, a stark reversal for a corridor that commanded some of the highest lab rents in the country just a few years ago. Genentech, South San Francisco's largest biotech employer and the anchor of its innovation identity, filed WARN Act notices covering 489 workers in 2025. Arsenal Biosciences cut 100 positions at its South San Francisco facility, and Sutro Biopharma eliminated nearly half its staff. Across the broader Bay Area, life sciences vacancy stood at 30.2 percent in the fourth quarter of 2025, though that figure marked the first improvement in two years, ticking down from 32.8 percent the prior quarter as the region absorbed slightly more space than it returned to market.

South San Francisco has carried the designation of birthplace of modern biotechnology since Genentech was founded and headquartered there, and the city built its civic and economic identity around that legacy. Pfizer's exit, just three years after it arrived via the GBT acquisition, leaves 164,000 square feet of purpose-built lab space seeking a new occupant at a moment when that task, in this market, is anything but straightforward.